Back to DNDN Stock Lookup

DNDN Related Analyst Comments

May 9, 2013 01:58 PM UPDATE: Stifel Nicolaus Downgrades Dendreon (DNDN) to Sell

Feb 25, 2013 02:05 PM Bearish Analyst Comments on Dendreon (DNDN)

Jan 30, 2013 09:57 AM Cantor Fitzgerald Raises Estimates and PT on Dendreon (DNDN) Ahead of Q4

Jan 24, 2013 10:49 AM Dendreon (DNDN) Ticks Higher; Analyst Sees 'Very High' Chance of EU Approving Provenge

Dec 3, 2012 11:12 AM Medivation's (MDVN) Xtandi Could See Strong Upside Following PREVAIL - Analyst

Dec 3, 2012 09:18 AM Uptake of Dendreon's (DNDN) Provenge Looking Grim, Even with Positive PII Outcome

Sep 5, 2012 08:32 AM Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Near Term Not Pretty

Aug 29, 2012 11:35 AM Data Confirms Zytiga is Killing Dendreon's (DNDN) Provenge, But Don't Put the Nail in the Coffin Yet

Aug 17, 2012 10:59 AM Dendreon (DNDN) Is Not Yet a 'Buy', But It's Getting Close

Jul 31, 2012 02:37 PM Barclays Cuts Numbers on Dendreon (DNDN); Facing An Uphill Battle Just To Gain Traction

Jul 31, 2012 09:04 AM Canaccord Genuity Cuts PT and Estimates on Dendreon (DNDN); Going Off the Rails on a Crazy Train

Jul 31, 2012 07:04 AM Jefferies Cuts Numbers on Dendreon (DNDN) After Poor Q2

Jul 31, 2012 06:32 AM Baird Lower Numbers on Dendreon (DNDN) But Says Restructuring the Right Move

Jul 17, 2012 09:10 AM RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results

Jun 21, 2012 12:28 PM Analyst Sees Dendreon's (DNDN) Efforts to Boost Provenge Demand Bearing Fruit in Q4; Shares Jump

Jun 19, 2012 09:14 AM Medivation (MDVN) Makes The Best Takeover Target, Not Dendreon (DNDN) - Jefferies

Jun 4, 2012 11:33 AM Deutsche Bank Defends Dendreon (DNDN) Despite Strong Zytiga Data; Maintains Buy

Jun 4, 2012 09:05 AM Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); New Treatments in Prostate Cancer Could Leave Provenge Behind

Jun 4, 2012 08:55 AM Baird Said Road Getting Tougher for Dendreon (DNDN)

Jun 4, 2012 07:45 AM Dendreon (DNDN) Competition Shadow Looms Larger After ASCO - Jefferies

May 23, 2012 08:53 AM Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN) After Meeting with Management

May 17, 2012 10:40 AM Dendreon (DNDN) Hit On Various Worries, Deutsche Bank Defends

May 8, 2012 09:21 AM Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN); Cutting Estimates After Q1 Results

Apr 20, 2012 10:05 AM Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

Apr 12, 2012 09:52 AM Citi Cuts Dendreon (DNDN) Price Target to $10 Amid 'Significant Threats to Provenge'

Mar 12, 2012 10:44 AM Canaccord Genuity Morning Coffee on Dendreon (DNDN) and Johnson & Johnson (JNJ): Honeydew Sized Prostate

Mar 9, 2012 10:21 AM Canaccord Genuity Reiterates a 'Buy' on Dendreon (DNDN); Buying On Weakness

Mar 9, 2012 08:59 AM Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Understanding Where A Catalyst For Valuation Expansion Will Come From

Mar 8, 2012 12:18 PM Dendreon's (DNDN) Provenge Hit With a Setback, But Valuation Getting Interesting - Baird

Mar 8, 2012 09:30 AM Deutsche Bank Maintains a 'Buy' on Dendreon (DNDN): Buyers on Any Weakness

Feb 28, 2012 01:31 PM Canaccord Genuity Cuts Price Target on Dendreon (DNDN) After Q4, But Keeps Buy Rating

Feb 28, 2012 09:52 AM Goldman Sachs Said Q4 Call Again Raises Dendreon (DNDN) Provenge Concerns

Feb 27, 2012 03:46 PM Baird Maintains a 'Neutral' on Dendreon (DNDN); Provenge Inflection Point Still Lacking

Feb 27, 2012 01:34 PM Brean Murray Carret & Co. Debates Survival of Dendreon (DNDN) Long-Term with Oral Competition; Maintains 'Sell'

Feb 7, 2012 08:28 AM Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval

Feb 1, 2012 03:42 PM Baird Raises Its Price Target On Dendreon (DNDN) After New CEO, But Says Don't Count On a Takeout

Feb 1, 2012 08:50 AM Brean Murray Sees Medivation (MDVN) As a Takeout Target After Strong Data, Sees "Beginning of the End" for Dendreon's (DNDN) Provenge

Feb 1, 2012 08:44 AM Deutsche Bank Says Dendreon (DNDN) CEO Departure a "Surprise," But New CEO Brings M&A History

Jan 6, 2012 03:21 PM Shares of Dendreon (DNDN) Higher Again; Several Firms Out With Mixed Comments

Jan 6, 2012 11:15 AM Owning Biotech Launch Stocks Is One Strategy To Capture Upside - Goldman Sachs

Jan 6, 2012 09:25 AM Canaccord Genuity Maintains a 'Buy' on Dendreon (DNDN); Raising Numbers After Q4 Provenge Sales Beat

Jan 6, 2012 07:11 AM Baird Reiterates a 'Neutral' on Dendreon (DNDN); Behind Strong Pre-Release: New Med/Onc Survey a Mixed Bag for Provenge

Jan 5, 2012 12:05 PM Brean Murray Carret & Co. Maintains a 'Sell' on Dendreon (DNDN); Beats 4Q11 Revenue For Sure, But Competitive Landscape Should Change

Jan 5, 2012 11:36 AM Wall Street Mostly Positive On Today's Dendreon (DNDN) News, But Mixed Over Near-Term

Jan 4, 2012 11:12 AM Goldman Sachs Highlights Best and Worst in Biotech for 2012

Dec 28, 2011 07:42 AM Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)

Dec 23, 2011 07:35 AM Needham & Company 2012 Biotech Preview

Dec 15, 2011 11:41 AM Biotech M&A Will Be In Focus in 2012 - Goldman

Dec 7, 2011 10:06 AM Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); Sells Victrelis Royalty for $125M, Delaying Inevitable Financing

Dec 6, 2011 03:44 PM Baird Maintains a 'Neutral' on Dendreon (DNDN); Victrelis Transaction Decreases Likelihood of Another Capital Raise

Back to DNDN Stock Lookup